Renaissance Technologies
BBIO icon

Renaissance Technologies’s BridgeBio Pharma BBIO Stock Holding History

Renaissance Technologies’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.2M Buy
+365,772
New +$26.5M 0.04% 538
2025
Q4 		– Sell
-322,246
Closed -$16.7M – 3246
2025
Q3 		$16.7M Buy
322,246
+76,300
+31% +$3.72M 0.02% 819
2025
Q2 		$10.6M Buy
+245,946
New +$8.95M 0.01% 1028
2023
Q4 		– Sell
-584,146
Closed -$15.4M – 3736
2023
Q3 		$15.4M Buy
+584,146
New +$16.6M 0.03% 689
2023
Q2 		– Sell
-763,746
Closed -$12.7M – 3910
2023
Q1 		$12.7M Sell
763,746
-266,200
-26% -$3.1M 0.02% 965
2022
Q4 		$7.85M Sell
1,029,946
-336,800
-25% -$3.22M 0.01% 1237
2022
Q3 		$13.6M Buy
1,366,746
+953,500
+231% +$9.91M 0.02% 869
2022
Q2 		$3.75M Buy
+413,246
New +$3.46M ﹤0.01% 1765
2021
Q2 		– Sell
-118,546
Closed -$7.3M – 3452
2021
Q1 		$7.3M Buy
+118,546
New +$7.76M 0.01% 1400

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies's BBIO Position: Q1 2026 in Review

Renaissance Technologies opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 365,772 shares worth $27.2M. The stake represents 0.04% of the portfolio and ranks #538 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in BBIO as recently as Q3 2025.

Renaissance Technologies first reported a position in BBIO in Q1 2021 and has held it in 9 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Renaissance Technologies held 365,772 shares of BridgeBio Pharma worth $27.2M as of Q1 2026.
  • BridgeBio Pharma was a new Renaissance Technologies position in Q1 2026.
  • BridgeBio Pharma made up 0.04% of Renaissance Technologies's portfolio in Q1 2026, its #538 holding.
  • Renaissance Technologies first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 9 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.